Company intelligence / Profile preview

Enigma

Knoxville, Tennessee, USA

Ownership: Private
Development stage: Other

Overview

Developing novel PET imaging biomarkers including α-synuclein tracer (funded by MJFF grant) and 4R Tau tracers; previously provided MK-6240 (florquinitau F-18) and NAV-4694 (FDA NDA accepted for Alzheimer's Tau PET); FDA accepted NDA for MK-6240.

Therapeutic areas: Neurology
Modalities: Radiopharmaceutical
Industry: Medical Imaging

Partnerships

Alamar BiosciencesAbbVieThe Michael J. Fox FoundationMeilleur Technologies, Inc.

Beyond the preview

Go deeper on Enigma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enigma.

Explore the full profile